[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Massachusetts General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":638},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,397,0,25,[9,46,75,98,129,159,180,209,230,252,278,301,328,358,385,403,425,448,470,494,514,538,564,587,613],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636655","early-phase-1-identifying-oxytocin-deficiency-in-pediatric-patients-with-pituitary-disease-100636655",false,"NCT07568509","Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease","Identifying a Provocation Test for Diagnosis of Oxytocin Deficiency in Youth With Hypopituitarism","Pedi-EVOLVE","Inclusion criteria (participants with AVP-D):\n\n* AVP-D diagnosed in clinic using standard of care diagnostic tools;\n* Stable pituitary hormone replacement (no change in dose of hormone replacement in six weeks prior to baseline);\n* If on estrogen\u002Fprogestin, female participants agree to stop for at least 6 weeks prior to Main study visits;\n* English language proficiency.\n\nInclusion criteria (participants with hypopituitary disease):\n\n* Hypopituitary disease diagnosis;\n* If receiving pituitary hormone replacement, no change in dose in six weeks prior to baseline);\n* If on estrogen\u002Fprogestin, participants agree to stop for at least 6 weeks prior to Main study visits;\n* English language proficiency.\n\nExclusion criteria (all participants):\n\n* History of pulmonary embolism or unprovoked deep venous thrombosis;\n* History of breast\u002Fendometrial cancer as well as current therapies on estrogen modulators\u002Fblockers (i.e., tamoxifen, raloxifene, aromatase inhibitors);\n* History of stroke, transient ischemic attack, myocardial infarction, angina pectoris, or peripheral arterial disease;\n* Pregnancy or breastfeeding within the last 8 weeks;\n* Medication changes within 2 weeks of enrollment or within 5 half-lives of the respective medication;\n* History of stage 3 chronic kidney disease or cirrhosis;\n* Any significant illness or condition that the investigator determines could interfere with study participation, data collection or safety;\n* Active tobacco smoking or nicotine patch use;\n* Psychosis or active suicidality.","ALL","7 Years","21 Years",{"count":22,"type":23},20,"ESTIMATED","INTERVENTIONAL",[26],"EARLY_PHASE1","An open-labeled, interventional pilot trial, 10 youth with AVP-D and 10 PD matched for age, sex, and BMI will be recruited from Pediatric Endocrinology and Neuroendocrinology at Massachusetts General Hospital and in the community. This study tests the hypothesis that oral estrogen\u002Fprogestin will stimulate endogenous oxytocin release in control subjects. Eligible participants will receive two tablets in a single administration containing a total of 1 mg of norethindrone acetate 70 mcg of ethinyl estradiol. Sampling for blood and saliva will take place at baseline and approximately 24 hours following study drug administration. Neuropsychological assessment (anxiety, mood and emotion regulation; impulse control; aberrant eating behaviors; social cognition and functioning; quality of life) will be assessed at baseline to characterize the study population.",[29,30,31,32],"Arginine Vasopressin Deficiency","Oxytocin Deficiency","Pediatric Disease","Hypopituitarism","RECRUITING","2026-08-20",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":37},"2026-08-17",{"date":41,"type":23},"2027-04",{"name":43,"class":44},"Massachusetts General Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100625015","a-natural-history-study-of-angelman-syndrome-100625015","NCT07417137","A Natural History Study of Angelman Syndrome","A Longitudinal Natural History Study of Adults and Children With Angelman Syndrome","GLOW-AS","Inclusion Criteria:\n\n* The participant has a primary clinical diagnosis of Angelman syndrome with documented genetic variation(s) affecting the function of the UBE3A gene within the human 15q11.2-q13.3 locus. Co-occurring conditions (e.g., autism spectrum disorder, cerebral palsy, intellectual disability) are permitted; however, Angelman syndrome must be the primary clinical diagnosis.\n* The participant is male or female (assigned sex at birth) and aged ≥1 year at the initial study visit.\n* The participant has a study partner who meets the study partner criteria below.\n* The participant, if unable to provide informed consent, has an appropriate surrogate who is at least 18 years of age and willing and able to provide informed consent on behalf of the participant in accordance with current International Council for Harmonisation (ICH) guidelines and applicable institutional regulations.\n\nIndividuals must satisfy the following criteria to be enrolled as study partners:\n\n* The study partner is a parent or primary caregiver who is at least 18 years of age.\n* The study partner has consistent contact with the participant and, in the opinion of the investigator, is sufficiently knowledgeable about the participant's ongoing condition to provide accurate and current information.\n* The study partner has sufficient English-language proficiency to complete study partner assessments.\n* The study partner is willing and able to provide informed consent on their own behalf in accordance with ICH guidelines and applicable institutional regulations.\n* The study partner is, in the opinion of the investigator, reliable and competent; willing and able to accompany the participant to all study visits and comply with study procedures; reachable by telephone or email as needed; and sufficiently knowledgeable about the participant's ongoing condition(s) to provide accurate and current information regarding the participant's health and well-being.\n\nExclusion Criteria:\n\n* The participant has at least one additional known genetic abnormality outside the human 15q11.2-q13.3 locus causing a probable or known developmental disability.\n* At least one standard-of-care treatment (medication or adjunctive therapy) used by the participant was changed during the 28 days (4 weeks) prior to the first study visit. Treatments include, but are not limited to, doses of anti-epileptic medications, behavioral management medications, sleep medications, gabapentin, cannabidiol, special diets, supplements, speech therapy, occupational therapy, applied behavioral analysis (ABA), psychosocial interventions, physical therapy, or nutritional support.\n* The participant has unstable epilepsy, defined as having an emergency department visit or hospitalization for seizure-related concerns within the 28 days (4 weeks) preceding the initial study visit.\n* The participant is of childbearing potential and is either pregnant, breastfeeding, or not using an adequate method of contraception; abstinence is acceptable.\n* The participant has a clinically relevant history of malignancy; clinically significant abnormal test results; clinically significant cardiovascular, hematologic, hepatic, muscular, neurologic, or renal disease; or has experienced other clinical events which, in the opinion of the investigator, render participation unsuitable.\n* The participant has a lifetime history of treatment with any cell- or gene-based therapy, including antisense oligonucleotides or gene-editing therapies.\n* The participant has received any investigational therapy other than a cell- or gene-based therapy within 28 days or 5 half-lives (whichever is longer) preceding the initial study visit.\n* The participant is currently enrolled or plans to enroll in an interventional study involving an investigational agent or device during the planned observation period.\n* The participant has a known contraindication to electroencephalography, actigraphy, or any other study procedure described in the schedule of assessments.\n* The participant or study partner is, in the opinion of the investigator, unsuitable for participation in any other way, including an inability to fulfill study requirements.","1 Year",{"count":56,"type":23},40,"OBSERVATIONAL","The goal of this observational study is to learn about the natural progression of Angelman syndrome (AS) in children and adults with a confirmed genetic diagnosis of AS. The main questions it aims to answer are:\n\n* How do developmental skills, such as communication, motor abilities, and adaptive behaviors, change over a 1-year period in people with AS?\n* Are there specific patterns in brain activity or sleep that are associated with changes in AS symptoms over time?\n\nParticipants will:\n\n* Attend 3 in-person and 2 virtual study visits over 1 year for assessments.\n* Complete tests and questionnaires about development, behaviors, and sleep with the help of their caregivers.\n* Undergo electroencephalograms (EEGs) to measure brain activity and wear a sleep-monitoring device at home (to collect actigraphy data).",[60,61],"Angelman Syndrome","Neurodevelopmental Conditions",[63,64,52,65,66,67],"Angelman syndrome","Angelman","AS","Natural History","Sleep","2026-08-19",{"date":36,"type":37},{"date":71,"type":23},"2026-08",{"date":73,"type":23},"2029-09",{"name":43,"class":44},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":45},"100582964","pain-disengagement-training-open-pilot-100582964","NCT06870162","Pain Disengagement Training (Open Pilot)","Pain Disengagement Training: A Self-directed Intervention for Pain Catastrophizing (Open Pilot)","Inclusion Criteria:\n\n1. Outpatient adults (i.e., greater than or equal to 18)\n2. Has self reported chronic musculoskeletal pain (i.e., pain persisting for at least 3 months)\n3. Pain score greater than or equal to 4 (moderate) on the Numerical Rating Scale\n4. Pain catastrophizing score greater than or equal to 20 on Pain Catastrophizing Scale\n5. Willingness to engage in a writing-based intervention and self-reported ability to write or type for at least 30 minutes in a sitting\n6. Received care at Massachusetts General Hospital\n7. English verbal and writing fluency\n\nExclusion Criteria:\n\n1. Clinically significant change in therapy or medication in the past 3 months\n2. Severe untreated mental health condition (e.g., psychosis)\n3. Active suicidality with history of plan or current intent\n4. Serious illness expected to worsen in the next 6 months (e.g., cancer)\n5. Untreated substance use problem that, per patient's self-report, would interfere with the ability to complete the intervention.","18 Years",{"count":84,"type":23},10,[86],"NA","The investigators aim to conduct an open pilot trial to determine the initial feasibility of a self-directed writing-based intervention in individuals with chronic musculoskeletal pain and elevated pain catastrophizing. The investigators will assess the feasibility of recruitment, acceptability of the treatment, credibility and participant satisfaction, treatment adherence, and feasibility of assessments following pre-specified benchmarks.",[89],"Chronic Musculoskeletal Pain",[91],"pain catastrophizing",{"date":36,"type":37},{"date":94,"type":37},"2025-10-14",{"date":96,"type":23},"2026-12-10",{"name":43,"class":44},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":24,"phases":108,"briefSummary":109,"conditions":110,"keywords":118,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100647447","brostrom-chronic-lateral-ankle-instability-repairs-augmented-with-biobrace-100647447","NCT07708584","Brostrom Chronic Lateral Ankle Instability Repairs Augmented With BioBrace®","The Effect of Augmented Brostrom Repair Using Bioinductive Implant in Patients With Lateral Ankle Instability","Inclusion Criteria:\n\n* Age 18-65 years\n* Chronic lateral ankle instability (\\>3 months) confirmed by clinical examination (positive anterior drawer test or talar tilt \\>10°) and imaging (stress X-ray or MRI).\n* No prior ankle surgery on the affected limb.\n* Willingness to follow postoperative visits and rehabilitation protocols and filling out the patient reported outcome measures (PROMs) forms.\n\nExclusion Criteria:\n\n* BMI\\>40\n* Significant secondary procedures done at the time of repair, including micro-fracture, or any other treatment of osteochondral lesions of the talus or tibia.\n* Concomitant deltoid ligament insufficiency.\n* Any worker's compensation case or any subject with a history of infection of the ankle predating the ankle repair. Current orthopedic issues, not related to the ankle, that prevented the patient from performing the functional tests.\n* Concomitant osteochondral lesions, significant degenerative changes, or severe varus\u002Fvalgus deformity, neuromuscular disorders or non-adherence concerns.\n* Pregnant\n* Diagnosis of Ehlers-Danlos Syndrome or other connective tissue \u002F hyperlaxity disorder.\n* Prior revision ankle ligament surgery on the affected limb (any revision Broström or lateral ligament reconstruction).","65 Years",{"count":107,"type":23},75,[86],"The purpose of this investigation is to evaluate pre- and post-operative patient reported outcomes and functional scores after open non-augmented Broström repair or open Broström repair augmented with the BioBrace Implant.",[111,112,113,114,115,116,117],"Lateral Ankle Instability","Chronic Lateral Ankle Instability","Brostrom Procedure","ATFL","Anterior Talofibular Ligament","Ankle","Bioinductive Implant",[111,119,117,114,115,113,120,116],"Brostrom Repair","Ankle Surgery","2026-08-18",{"date":68,"type":37},{"date":124,"type":23},"2026-09",{"date":126,"type":23},"2028-06",{"name":43,"class":44},2,{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":136,"sex":18,"minAge":82,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":24,"phases":140,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":45},"100497633","oct-vibrography-for-biomechanical-properties-of-tissues-100497633","NCT05759780","OCT Vibrography for Biomechanical Properties of Tissues","A Study to Test the Potential of OCT Vibrography for Measuring Biomechanical Properties of Tissues","Group 1:\n\nInclusion criteria:\n\n• Subjects with healthy eyes (age 18 - 75, N = 50)\n\nExclusion criteria:\n\n* Subjects with history of eye diseases, and previous eye surgeries.\n* Subjects with diabetes, glaucoma family history\n* Subjects allergic to anesthetic eyedrop, especially proparacaine\n* Subjects with severe allergy\n* Subjects who have difficulty biting\n* Subjects who have recurrent corneal erosion\n\nGroup 2:\n\nInclusion criteria:\n\n• Subjects with healthy skin (age 18 - 75, N = 10)\n\nExclusion criteria:\n\n• Subjects with open cuts\u002Fsores on the skin, skin infection, or any contagious skin condition\n\nGroup 3:\n\nInclusion criteria:\n\n• Subjects with healthy gingiva (age 18 - 75, N = 10)\n\nExclusion criteria:\n\n• Subjects with open cuts\u002Fsores on the gingiva, gingiva infection, or any contagious gingiva condition\n\nGroup 4:\n\nInclusion criteria:\n\n• Mild or moderate keratoconus subjects (age 18 - 40, N = 20)\n\nExclusion criteria:\n\n• Subjects with K-max above 60 diopters (Pentacam imaging) are excluded",true,"75 Years",{"count":139,"type":23},90,[86],"The overall goal of this study is to develop OCT Vibrography (aka OCT elastography) as a novel tool for measuring biomechanical properties of human tissues in vivo.",[143,144,145],"Cornea","Skin Diseases","Gingival Diseases",[147,148,149,150,151,152],"biomechanics","cornea","skin","gingiva","optical coherence tomography","vibrography",{"date":68,"type":37},{"date":155,"type":37},"2023-08-19",{"date":157,"type":23},"2026-08-28",{"name":43,"class":44},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":168,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},"100490113","phase-2-from-nerve-to-brain-toward-a-mechanistic-understanding-of-spinal-cord-stimulation-in-human-subjects-100490113","NCT05661903","From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects","Inclusion Criteria:\n\n* Aged 18 to 80\n* Capable of providing informed consent and following trial procedures, including capacity to complete self-reported measures of pain, function, and other outcomes\n* Stably implanted spinal cord or dorsal root ganglion stimulator\n* Device is to treat back\u002Fradicular lower extremity pain or neck\u002Farm pain\n* Device with a paresthesia-free setting\n\nExclusion Criteria:\n\n* Patients who are not on a stable dose of opioids or are on a stable dose greater than 100 MME\u002Fday per day within the two months prior to enrollment, or those who are unwilling to maintain a stable dose of opioids throughout the duration of the study\n* The investigator concludes that the participant is unable to differentiate back or neck\u002Farm pain from other pains\n* Systemic or psychiatric illness that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial\n* Other factor that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial or tolerate the study procedures\n\nDropout Criteria for Optional Imaging\n\n* Stimulation device is not 3 Tesla magnetic resonance imaging compliant\n* Contraindications to magnetic resonance imaging and\u002For positron emission tomography scanning (including presence of a cardiac pacemaker or pacemaker wires, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia)\n* Pregnant or breastfeeding\n* Participants with a low affinity binder phenotype based off testing for the Ala147Thr polymorphism.\n* Current or recent use of benzodiazepines (except for alprazolam, clonazepam, and lorazepam). Recent use will be defined based off the benzodiazepines half-life, such that patients who stopped taking the medication at least five half-lives ago will be considered eligible for scanning.\n* Subjects who have exceeded (or would exceed if they were to participate) the yearly amount of allowable radiation, as defined by the Radiation Safety Committee\n* In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., unlikely to remain still during the imaging procedures).","80 Years",{"count":167,"type":23},180,[169],"PHASE2","This is a multicenter prospective study of patients who currently have stably implanted spinal cord simulators. Patients will be randomly assigned to turn on or off their spinal cord stimulators for two week intervals up to six weeks after enrollment, and on the final day of study participation, for one hour intervals, in a multi-crossover design. In a subset of patients we will also perform combined positron emission tomography\u002Fmagnetic resonance imaging at baseline, week 2 and week 4.",[172],"Chronic Pain",{"date":34,"type":37},{"date":175,"type":37},"2023-06-08",{"date":177,"type":23},"2027-08-31",{"name":43,"class":44},3,{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":190,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":208},"100465071","phase-3-abatacept-in-immune-checkpoint-inhibitor-myocarditis-100465071","NCT05335928","Abatacept in Immune Checkpoint Inhibitor Myocarditis","AbatacepT foR ImmUne Checkpoint Inhibitor Associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in ICI Myocarditis","ATRIUM","Inclusion Criteria:\n\n1. Must have provided informed consent in a manner approved by the Investigator's Institutional Review Board (IRB) prior to any study-related procedure being performed. If a participant is unable to provide informed consent due to his\u002Fher medical condition, the participant's legally authorized representative may consent on behalf of the study participant, as permitted by local law and institutional Standard Operating Procedures;\n2. Aged greater than or equal to 18 years at the time of informed consent;\n3. Recent use of an FDA-approved immune checkpoint inhibitor (ICI, defined as administered an immune checkpoint inhibitor ≤ 6 months of myocarditis diagnosis), alone or in combination with other cancer therapies (i.e. chemotherapy, radiation therapy or targeted therapy). The FDA-approved ICI could be given as part of a clinical trial but not in combination with a new investigational agent which may cause myocarditis;\n4. A diagnosis of myocarditis.\n5. Hospitalized at the time of randomization;\n6. On 1000 mg of solumedrol per day for myocarditis or with an intent to initiate 1000 mg of solumedrol per day for myocarditis within 24 hours of first administration of study drug;\n7. Serum evidence of ongoing myocardial injury: Serum evidence of ongoing myocardial injury will be defined as an institutional troponin (either conventional or high-sensitivity troponin I or T, using the standard institutional assay) with a value that is ≥5 times the upper limit of the reference standard normal for that institution. The troponin assay may be adjusted based on sex depending on institutional standards. This value of troponin of ≥5 times above the institutional upper limits of normal value must be noted within 10 days prior to potential randomization. The 10-day period can be in the outpatient or inpatient setting. For example, a participant with a troponin value that on one occasion was ≥5 times the upper limits of institutional normal in the 10-day window prior to potential randomization (whether in the inpatient or outpatient setting), but later decreases below that threshold, typically due to starting corticosteroids, would still be considered eligible;\n8. The following laboratory parameters, not older than 48 hours at the time of randomization, and measured as part of usual care:\n\n   * Total white blood cell (WBC) count \\>2,500\u002Fμl\n   * Absolute neutrophil count (ANC) \\>1,500\u002FμL\n   * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\\u003C20 times the upper limit of the institutional normal ranges;\n9. Women of childbearing potential (i.e., not postmenopausal, or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test prior to randomization. Participating women of childbearing potential must be willing to consistently use effective methods of contraception from screening until at least 90 days after administration of the last dose of study drug. Participating men must also be willing to consistently use effective methods of contraception from screening until at least 90 days after administration of the last dose of study drug; and\n10. Must be willing and able to abide by all study requirements and restrictions.\n\nExclusion Criteria:\n\n1. Must not have experienced any of the following (as defined in the section on the primary endpoint) in the 30-day period prior to randomization:\n\n   * A sudden cardiac arrest\n   * Cardiogenic shock as defined. A significant bradyarrhythmia (Mobitz type II second degree atrioventricular block or third degree (complete) atrio-ventricular (AV) block, for which an intervention with a temporary or permanent pacemaker is completed or recommended).\n   * A significant tachyarrhythmia (ventricular fibrillation of any duration or sustained ventricular tachycardia (\\>30 seconds, \\>120 beats per minute); or a ventricular tachyarrhythmia requiring intervention.\n2. Recent (≤2 month) exposure to abatacept or belatacept.\n3. Concurrent or recent (≤2 month) use of the following non-corticosteroid immunosuppressive therapies prior to randomization: mycophenolate, JAK STAT inhibitors (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib), tacrolimus, anti-thymocyte globulin, alemtuzumab, infliximab, and plasma exchange. The use of intravenous immunoglobulin is permitted prior to randomization and during study treatment.\n4. Currently enrolled in another interventional study utilizing systemic agents for the management of ICI-related toxicities.\n5. Female who is pregnant, breastfeeding, or is considering becoming pregnant during the study or for approximately 90 days after the last dose of study drug.\n6. Male who is considering fathering a child or donating sperm during the study or for approximately 30 days after the last dose of study drug.\n7. Any active, chronic, or recurrent viral infection that, based on the investigator's clinical assessment, makes the participant an unsuitable candidate for the study. These may include hepatitis B virus (HBV) or hepatitis C virus (HCV), recurrent or disseminated (even a single episode) herpes zoster, and disseminated (even a single episode) herpes simplex. Active HBV and HCV are defined as: HBV: hepatitis B surface antigen (HBs Ag) positive (+) or detected sensitivity on the HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for Hepatitis B core antibody (HBc Ab) positive (+) participants; HCV: HCV ribonucleic acid (RNA) detectable in any participant with anti-HCV antibody (HCV Ab). Patients with active Covid-19 infection will be excluded. This is defined as the period of ongoing symptoms in the setting of a positive Covid-19 test, or until 10 days after symptom onset and after resolution of fever for at least 24 hours, without the use of fever-reducing medications.\n8. Known active tuberculosis (TB), history of incompletely treated TB, suspected or known extrapulmonary TB, suspected or known systemic bacterial or fungal infections;\n9. Receipt of any live vaccine within four weeks prior to the first dose of study drug, or expected need of live vaccination during study participation including at least 90 days after the last dose of IV study drug.\n10. Any medical condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or interpretation of the study results, or that would, in the opinion of the Investigator, increase the risk of the participant by participating in the study.\n11. Any factors that, in the Investigator's opinion, are likely to interfere with study procedures, such as history of noncompliance with scheduled appointments.",{"count":189,"type":23},390,[191],"PHASE3","The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.",[194,195],"Myocarditis Acute","Cancer",[197,198,199,200,201],"Immune checkpoint Inhibitor","Myocarditis","Abatacept","Immune therapy","Immune related adverse events",{"date":34,"type":37},{"date":204,"type":37},"2022-07-02",{"date":206,"type":23},"2029-10-09",{"name":43,"class":44},31,{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":136,"sex":18,"minAge":82,"maxAge":105,"enrollmentInfo":216,"targetDuration":4,"studyType":24,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":45},"100652428","identifying-multidimensional-signatures-of-gastric-interoception-in-functional-dyspepsia-100652428","NCT07772167","Identifying Multidimensional Signatures of Gastric Interoception in Functional Dyspepsia","IMAGINE","Participant Inclusion Criteria--\n\nFunctional Dyspepsia Group:\n\n* Males and females; ages 18-65 years\n* Rome V functional dyspepsia post-prandial distress syndrome subtype\n* Negative upper endoscopy or upper GI series to rule out structural\u002Forganic cause for FD\n* greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)\n* Fluent in English\n* Willing and able to provide informed consent\n* Stable dose for 30 days prior to Visit 1 if on a neuropsychiatric medication (e.g., TCA, SNRI, SSRI mirtazapine, atypical antipsychotic, gabapentin, buspirone, pregabalin)\n* No current plans to initiate a new or change dosing on a neuropsychiatric medication within the study period\n\nAnorexia Nervosa Group:\n\n* Males and females; ages 18-65 years\n* DSM-5 anorexia restricting-type by the Eating Disorder Module in the Diagnostic Interview for Mood, Anxiety, and OCD and related Neuropsychiatric Disorders (DIAMOND)\n* greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)\n* Fluent in English\n* Willing and able to provide informed consent\n* Stable dose for 30 days prior to Visit 1 if on an SSRI\n* No current plans to initiate a new neuromodulator\n* No current plans to initiate a new SSRI or change dosing on an SSRI\n\nHealthy Controls:\n\n* Males and females; ages 18-65 years\n* BMI greater than or equal to 18.5 kg\u002Fm2\n* Fluent in English\n* Willing and able to provide informed consent\n\nParticipant Exclusion Criteria--\n\nFunctional Dyspepsia Group:\n\n* Presence of other conditions that could explain the patient's symptoms by medical chart:\n\n  * Pyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT)\n  * Active H.pylori (by CLO test or stool antigen test)\n  * Active inflammatory bowel disease\n  * Eosinophilic gastroenteritis or eosinophilic esophagitis\n  * Acute renal failure\n  * Chronic renal failure (serum creatinine \\>3 mg\u002FdL) and\u002For on hemodialysis or peritoneal dialysis\n  * Acute liver failure\n  * Any acute gastrointestinal process\n  * Any plausible structural or metabolic causes\n  * Heartburn as predominant symptom\n  * History of peptic ulcer\n* Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed)\n* Endorses any contraindications to MRI\n* Body weight of 450 lbs or greater or BMI of 50 kg\u002Fm2 or greater (limit of MRI table)\n* Allergy to pineapple (used in the test meal during MRI)\n* History of GI tract surgery or any serious medical condition (e.g., cancer)\n* Pregnancy\u002Fbreastfeeding within the last 8 weeks\n* Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart\n* Narcotic analgesics greater than three days per week\n* Cannabinoid use greater than three days per week\n* Intellectual disability by history\n* Illiteracy\n* History of weight\u002Fshape-based eating disorder including anorexia nervosa by DIAMOND\n* Current binge eating by DIAMOND\n* Current self-induced vomiting by DIAMOND\n* Current laxative or diuretic misuse by DIAMOND\n* Current substance\u002Falcohol use disorder within past year by DIAMOND\n* Current\u002Fhistory of psychosis by DIAMOND\n* Current mania by DIAMOND\n* Active suicidal ideation by modified DIAMOND abbreviated suicide module; passive suicidal ideation is allowed\n* Inability or unwillingness to consume food by mouth\n* Inability to provide informed consent\n\nAnorexia Nervosa Group:\n\n* Diagnosis of chronic gastrointestinal disorder\n* Rome V functional dyspepsia\n* Endorses any contraindications to MRI\n* Body weight of 450 lbs or greater or BMI of 50 kg\u002Fm2 or greater (limit of MRI table)\n* Allergy to pineapple (used in the test meal during MRI)\n* History of GI tract surgery or any serious medical condition (e.g., cancer)\n* Pregnancy\u002Fbreastfeeding within the last 8 weeks\n* Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart\n* Narcotic analgesics greater than three days per week\n* Cannabinoid use greater than three days per week\n* Intellectual disability by history\n* Illiteracy\n* Current binge eating by DIAMOND\n* Current self-induced vomiting by DIAMOND\n* Current laxative or diuretic misuse by DIAMOND\n* Current substance\u002Falcohol use disorder within past year by DIAMOND\n* Current\u002Fhistory of psychosis by DIAMOND\n* Current mania by DIAMOND\n* Active suicidal ideation by DIAMOND abbreviated suicide module; passive suicidal ideation is allowed\n* Inability or unwillingness to consume food by mouth\n* Inability to provide informed consent\n* Current use of neuropsychiatric medication other than an SSRI (e.g., TCA, SNRI, mirtazapine, atypical antipsychotic, gabapentin, buspirone, pregabalin)\n\nHealthy Controls:\n\n* Diagnosis of chronic gastrointestinal or pain disorder\n* Rome V functional dyspepsia\n* greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)\n* Current use of a medication known to influence gastric sensorimotor functions (including neuromodulators and SSRIs)\n* Active psychiatric disorder including a feeding\u002Feating disorder by DIAMOND\n* Endorses any contraindications to MRI\n* Body weight of 450 lbs or greater or BMI of 50 kg\u002Fm2 or greater (limit of MRI table)\n* Allergy to pineapple (used in the test meal during MRI)\n* History of GI tract surgery or any serious medical condition (e.g., cancer)\n* Pregnancy\u002Fbreastfeeding within the last 8 weeks\n* Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart\n* Narcotic analgesics greater than three days per week\n* Cannabinoid use greater than three days per week\n* Intellectual disability by history\n* Illiteracy\n* Current binge eating by DIAMOND\n* Current self-induced vomiting by DIAMOND\n* Current laxative or diuretic misuse by DIAMOND\n* Current substance\u002Falcohol use disorder within past year by DIAMOND\n* Current\u002Fhistory of psychosis by DIAMOND\n* Current mania by DIAMOND\n* Active suicidal ideation by DIAMOND modified suicide module; passive suicidal ideation is allowed\n* Inability or unwillingness to consume food by mouth\n* Inability to provide informed consent",{"count":217,"type":23},150,[86],"This study is being conducted to investigate gut-brain communication in individuals with functional dyspepsia and anorexia nervosa. The hope is that what the investigators learn from this study will improve the understanding the conditions better to improve treatments.",[221,222],"Functional Dyspepsia","Anorexia Nervosa","2026-08-14",{"date":68,"type":37},{"date":226,"type":37},"2026-03-16",{"date":228,"type":23},"2031-03",{"name":43,"class":44},{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":24,"phases":238,"briefSummary":239,"conditions":240,"keywords":244,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":45},"100502712","pilot-study-of-health-systemcommunity-partnership-for-enhanced-outreach-to-prevent-suicide-attempts-100502712","NCT05825820","Pilot Study of Health System\u002FCommunity Partnership for Enhanced Outreach to Prevent Suicide Attempts","Pilot Study Health System\u002FCommunity Partnership for Enhanced Outreach to Prevent Suicide Attempts","Inclusion Criteria:\n\n1. Currently a patient being treated and evaluated by psychiatry service in an MGB ED\n2. Participants enrolled in another study (NCT05671133; PI Nock) conducted by the research team who fall into the top 50% of risk based on the suicide risk prediction algorithm used in that study\n3. Able to read English\n4. Ownership of a smartphone (iOS or Android) and consistent access to their smartphone following discharge from the current treatment unit or program; ability to be reliably contacted\n5. Willing to provide contact information for collateral contact\n6. Willing to share contact information and key clinical information with Samaritans of Boston\n7. Consent to unencrypted text or email communications\n8. Willing to provide social security number (SSN) or individual taxpayer identification number (ITIN) for study compensation\n\nExclusion Criteria:\n\n1. Any factor that impairs an individual's ability to comprehend and effectively participate in informed consent, including the presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, or acute intoxication\n2. Presence of extremely agitated or violent behavior at the time of consent or enrollment",{"count":22,"type":23},[86],"The goal of this clinical trial is to test an enhanced outreach intervention (EOI) delivered by Samaritans of Boston (a community organization that provides support during mental health crises) for people after they leave an emergency department (ED) visit for suicidal thoughts. The main questions the trial aims to answer are:\n\n* Is the EOI feasible and acceptable?\n* Can the EOI be delivered with fidelity by Samaritans staff?\n\nParticipants will:\n\n* Receive outreach (by call or text) once per week for 12 weeks after ED visit. During these conversations, Samaritans staff will ask participants questions about their suicidal thoughts and behaviors, develop and review a list of coping skills to use if they have suicidal thoughts, and discuss plans for receiving mental health care.\n* Receive caring messages from Samaritans staff at least once per week.\n* Be asked to complete monthly self-report questionnaires, and participate in a phone interview with study staff at the end of the study.",[241,242,243],"Suicide","Suicide, Attempted","Suicidal Ideation",[241,245],"Suicidal Thoughts",{"date":39,"type":37},{"date":248,"type":37},"2026-07-31",{"date":250,"type":23},"2027-02",{"name":43,"class":44},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":165,"enrollmentInfo":259,"targetDuration":4,"studyType":24,"phases":261,"briefSummary":262,"conditions":263,"keywords":266,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":45},"100500820","vascular-ards-recruitment-after-inhaled-nitric-oxide-100500820","NCT05801224","Vascular ARDS Recruitment After Inhaled Nitric Oxide","Regional Vascular Recruitment With Inhaled Nitric Oxide in Patients With ARDS","Inclusion Criteria:\n\n* Adult intubated and mechanically ventilated patients (≥ 18 years old) admitted to the intensive care unit (ICU)\n* ARDS diagnosis with mild to moderate severity by Berlin criteria1 (100 mmHg \\\u003C PaO2\u002FFiO2 \\\u003C= 300 mmHg)\n* Presence of an arterial line for blood gas measurement and blood pressure monitoring and of a central line for hypertonic saline injection\n\nExclusion Criteria:\n\n* Suspected pregnancy, pregnancy or less than six weeks postpartum\n* Younger than 18 years or older than 80 years\n* Baseline methemoglobin ≥ 5%\n* Subjects enrolled in another interventional research study\n* Presence of pneumothorax\n* Usage of any devices with electric current generation, such as a pacemaker or internal cardiac defibrillator\n* Preexisting chronic lung disease or pulmonary hypertension\n* Past medical history of lung malignancy or pneumonectomy, or lung transplant\n* Left ventricle ejection fraction \\\u003C20%\n* Hemodynamic instability is defined as:\n\n  * Persistent systolic blood pressure \\\u003C90 mmHg and\u002For \\>180 mmHg despite the use of vasopressor or vasodilators, or\n  * Requiring an increment in inotropic vasopressors over the past two hours just before enrollment: more than 15 mcg\u002Fmin for norepinephrine and dopamine, more than 10 mcg\u002Fmin in epinephrine, and more than 50 mcg\u002F min for phenylephrine.\n* Hypernatremia (serum sodium \\> 150 mEq\u002FL)\n* Patients cannot be enrolled for DECT if they have:\n\n  * History of allergic reaction to intravenous contrast\n  * Renal dysfunction on the day of the study (serum creatinine \\> 1.5 mg\u002FdL)",{"count":260,"type":23},70,[86],"Acute respiratory distress syndrome (ARDS) is when a person's lungs become inflamed, which can be caused by infection, trauma, surgery, blood transfusion, or burn. ARDS often leads to a situation where the person cannot breathe independently and needs machines' help. Once the lungs are inflamed, the small air sacs responsible for exchanging gases (i.e., ventilation) and the blood flow in the lungs (i.e., perfusion) can be affected. In the past, most research focused on studying ventilation physiology and how to help people breathe with machines. Less was done on perfusion because it requires imaging techniques such as computed tomography with intravenous contrast and radiation. One treatment option for low oxygen levels is inhaled nitric oxide (iNO), a gas that can dilate the lung blood vessels and improve oxygenation; however, it is not always clear whether this treatment will work.\n\nProne position has been used for several years in the care of ARDS patients and has been demonstrated to improve survival in more severe patients. It is not known how iNO and prone positioning interact in determining the distribution of pulmonary perfusion and whether their combine use can benefit ARDS patients.\n\nElectrical Impedance Tomography (EIT) is a bedside and accessible imaging technique that is radiation-free and non-invasive and can potentially detect changes in lung perfusion. EIT can perform multiple measurements; it is portable and accessible. This prospective interventional study aims to assess changes in regional blood perfusion in the lungs of patients with ARDS in response to iNO and to prone positioning utilizing EIT. The main questions it aims to answer are:\n\n1. If EIT can measure lung regional perfusion response to an iNO challenge of 20ppm for 15 minutes.\n2. If EIT can measure the lung regional perfusion responses to prone position, applied alone and in combination with iNO.\n3. If EIT is comparable to dual-energy computed tomography (DECT), the gold-standard method, in the detection of changes in regional lung perfusion due to iNO.\n4. If EIT can be an imaging marker to identify ARDS severity\n\nParticipants will be divided into three cohorts:\n\n1. Sub-Cohort 1 (n=60): Participants will be asked to be monitored by EIT before, during, and after the administration of iNO (20 ppm) for 15 minutes (OFF-ON-OFF) in the supine position\n2. Sub-Cohort 2 (N=10): Participants will be asked to be monitored by EIT before and during the administration of iNO (20 ppm) for 15 minutes (OFF-ON) in both the supine and in the prone position. The same subjects will be monitored also with DECT in the supine position and then after 30 minutes in the prone position (without NO administration).\n3. Sub-Cohort 3 (N=10): In this subset of Sub-Cohort 1, subjects will be asked to be monitored also with DECT (in addition to EIT) in the supine body position before iNO and after 15 minutes while receiving iNO.",[264,265],"Acute Respiratory Distress Syndrome","Ventilation Perfusion Mismatch",[267,268,269,270,271],"Acute respiratory distress syndrome","Ventilation\u002Fperfusion mismatch","Electrical impedance tomography","Inhaled nitric oxide","Dual-energy computed tomography",{"date":121,"type":37},{"date":274,"type":37},"2026-07-10",{"date":276,"type":23},"2028-12-31",{"name":43,"class":44},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":24,"phases":286,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":294,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":298,"leadSponsor":300,"locationsCount":45},"100651949","training-on-systemic-and-organ-spec-pm-in-pc-100651949","NCT07768917","Training on Systemic and Organ Spec. PM in PC","Impact of Prescribed Physical Training on Systemic and Organ Specific Prognostic Markers in Prostate Cancer","Inclusion Criteria:\n\n* Have histologically or cytologically confirmed adenocarcinoma of the prostate\n* Have not received GnRH agonist or antagonist within the last 12 months\n* Planned for initiation of a GnRH agonist or antagonist or bilateral orchiectomy with an intended treatment duration of ≥ 6 months\n* Planned for initiation of radiation therapy to the prostate.\n* ECOG performance status of 0 or 1\n* Ability to understand and the willingness to sign a written informed consent document\n* Baseline serum total testosterone level \\> 230 ng\u002FdL (the accepted threshold for testosterone supplementation)\n* Speak English -\\>18 years of age\n\nExclusion Criteria:\n\n* Has a known medical condition that makes the subject unable to participate in exercise testing (e.g. unrevascularized coronary artery disease, moderate\u002Fsevere osteoarthritis, prior stroke, or other conditions)\n* Receiving or planned to receive other cancer therapy not included in Eligibility Criterion 3.1.3 (other than an antiandrogen during the first month of therapy)\n* The following populations will not be considered for inclusion on this trial.",{"count":22,"type":23},[86],"This research is being done to assess the impact of a supervised and structured strength and conditioning program on cardiac remodeling in participants with prostate cancer undergoing treatment with external beam radiation therapy and at least 6 months of Gonadotropin-releasing hormone (GnRH) therapy.",[289],"Prostate Cancer",[291,292,293],"Prescribed Physical Training","Exercise Program","Systemic and Organ Specific Prognostic Markers in Prostate Cancer","NOT_YET_RECRUITING","2026-08-12",{"date":39,"type":37},{"date":96,"type":23},{"date":299,"type":23},"2027-03-31",{"name":43,"class":44},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":24,"phases":312,"briefSummary":313,"conditions":314,"keywords":316,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":45},"100490314","phase-2-a-study-of-the-effects-of-oxytocin-in-adults-with-binge-eating-disorder-100490314","NCT05664516","A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Intranasal Oxytocin in Adults With Binge-eating Disorder","STROBE","Inclusion Criteria:\n\n* Males and females, 18-70 years old\n* BMI greater than or equal to 18.5\n* BED as assessed by Structured Clinical Interview for DSM-5 Disorders (SCID-5-RV) OR Other Specified Feeding or Eating Disorder (OSFED) - Binge-eating disorder (of low frequency and\u002For limited duration) (SCID-5-RV) OR Bulimia Nervosa (BN) through excessive exercise and\u002For fasting to avoid gaining weight after episodes of binge eating. For individuals with OSFED-BED, the frequency of subjective and objective binge eating episodes will meet the frequency (Criterion D) for BED.\n\nExclusion Criteria:\n\n* Substance use disorder active within the last 6 months, or clinical suspicion of ongoing substance use disorder at the discretion of the study clinician at the time of screening based on history and\u002For laboratory results\n* Medication changes that have not reached steady state concentration, measured by the equivalent of 5 half-lives of that medication\n* Use of medications for binge eating disorder or weight loss unless at a stable dose for at least 12 weeks\n* History of any of the following medical conditions: inflammatory bowel disease or untreated thyroid disease\n* Uncontrolled epilepsy (as defined by a seizure within the last 12 months)\n* Clinically relevant ventricular arrhythmias, coronary heart disease, known long QTc, and hypertrophic cardiomyopathy\n* Hematocrit \\>2% below normal\n* Hemoglobin A1c \\>8%\n* Use of insulin\n* ALT or AST \\>2.5 times upper limit of normal\n* Glomerular filtration rate \\\u003C 60 mL\u002Fmin\n* Hyponatremia. Note that, in order to be randomized, subjects must have Na ≥ 135 mEq\u002FL.\n* Pregnancy or breastfeeding\n* Unwilling to use a medically acceptable form of contraception throughout the study period (female of child-bearing potential only)\n* History of psychosis or active suicidal ideation\n* Major depressive disorder likely to require initiation or change in active treatment\n* Borderline personality disorder as assessed by the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD)\n* Current nicotine use, unless stable use for at least 12 weeks.\n* Participation in any clinical study involving an investigational drug, device, or biologic within 1 month of randomization\n* Any significant illness, condition, or medication that the Investigator determines could interfere with study participation and impact data collection or subject safety","70 Years",{"count":311,"type":23},60,[169],"This study evaluates the impact of intranasal oxytocin vs placebo in patients with binge eating disorder or episodes of binging. We hypothesize that 8 weeks of intranasal oxytocin vs placebo will improve clinical outcomes \\[reduction in bingeing frequency\\], and have a satisfactory safety and tolerability profile. We will also explore the predictive value of changes in homeostatic appetite, reward sensitivity, and impulse control, the identified underlying mediators, as assessed 4 weeks into the intervention, for treatment success after 8 weeks of the intervention.",[315],"Binge-eating Disorder",[317,318,319,320,321],"Binge","Binge-eating disorder","Oxytocin","Over-eating","Impulse Control",{"date":223,"type":37},{"date":324,"type":37},"2023-03-07",{"date":326,"type":23},"2027-02-28",{"name":43,"class":44},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":24,"phases":337,"briefSummary":338,"conditions":339,"keywords":344,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":45},"100620556","changing-lives-and-changing-outcomes-9-at-worcester-recovery-center-and-hospital-100620556","NCT07359157","Changing Lives and Changing Outcomes-9 at Worcester Recovery Center and Hospital","Changing Lives and Changing Outcomes-9 at Worcester Recovery Center and Hospital: Implementing and Evaluating A Mental Illness and Criminal Risk Focused Intervention for People With Serious Mental Illness","CLCO-9","Inclusion Criteria:\n\n* Currently hospitalized at Worcester Recovery Center and Hospital (WRCH)\n* At least 18 years old\n* Self-reported current or past legal involvement\n* Speaks English\n* For patients without a legally authorized representative (LAR): demonstrate capacity to consent per the Capacity Assessment Record (CAR).\n* For patients with an LAR: assent to participate.\n\nExclusion Criteria:\n\n* Hospital status that does not permit group attendance (e.g., room-based seclusion)",{"count":56,"type":23},[86],"People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement.\n\nThe investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims:\n\n1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH\n2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement\n3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement.\n\nTo test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment.\n\nAll patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.",[340,341,342,343],"Serious Mental Illness","Psychotic Disorder","Depression","Bipolar",[345,346,347,348,349,350],"serious mental illness","criminogenic risk","criminal legal involvement","treatment","forensic","state hospital","2026-08-11",{"date":295,"type":37},{"date":354,"type":37},"2026-02-05",{"date":356,"type":23},"2027-05-01",{"name":43,"class":44},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":24,"phases":366,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":128},"100578436","phase-2-outpatient-epcoritamab-as-2l-in-nte-rr-dlbcl-100578436","NCT06811272","Outpatient Epcoritamab in Large B-cell Lymphoma","A Phase 2 Study of Outpatient Epcoritamab in Large B-cell Lymphoma","Inclusion Criteria:\n\nFirst Line Cohort\n\n* No prior systemic antineoplastic therapy for large B-cell lymphoma.\n* Score of \"frail\" or \"unfit\" on Fondazione Italiana Linfomi simplified Geriatric Assessment (FIL sGA) (Appendix E).\n\nSecond Line Cohort\n\n* Relapsed or refractory disease treated with 1 prior systemic antineoplastic line of therapy that includes an anti-CD20 monoclonal antibody plus an anthracycline and\u002For an alkylating agent. Patients who have received more than 1 prior systemic antineoplastic line of therapy are not eligible.\n* Not a candidate for high dose chemotherapy and autologous stem cell transplant per the treating investigator, or patient refusal of high dose chemotherapy and autologous transplant.\n\nBoth Cohorts\n\n* Participants must have large B-cell lymphoma of one of the following histologic subtypes by WHO criteria:\n\n  * Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)\n  * High grade B-cell lymphoma (HGBCL) with rearrangements of MYC and BCL2 and\u002For BCL6\n  * HGBCL NOS\n  * EBV+ DLBCL\n  * Primary mediastinal B-cell lymphoma\n  * T-cell\u002Fhistiocyte rich LBCL\n  * Grade 3B follicular lymphoma\n  * Large B-cell lymphoma transformed from underlying indolent NHL\n* PET measurable disease per Lugano criteria (Section 10).\n* Age ≥18 years.\n* ECOG performance status 0-2 (Appendix A)\n* Participants must meet the following organ and marrow function as defined below:\n\n  * absolute neutrophil count ≥1,000\u002FmcL (Growth factor support as clinically indicated is permitted)\n  * platelets ≥75,000\u002FmcL (\\>50,000 in the presence of bone marrow involvement or splenomegaly; platelet transfusions as clinically indicated are permitted)\n  * Hemoglobin ≥8 g\u002FdL (\\>7 g\u002FdL in the presence of bone marrow involvement; blood transfusions as clinically indicated are permitted)\n* Participants must have adequate organ function as defined below (unless abnormalities are considered related to target organ involvement or compression by lymphoma):\n\n  * total bilirubin ≤ 1.5x institutional upper limit of normal (ULN) (Isolated bilirubin ≤3.0x ULN is acceptable if considered secondary to Gilbert's syndrome)\n  * AST(SGOT) and ALT(SGPT) ≤3.0x institutional ULN\n  * Creatinine clearance ≥40 mL\u002Fmin eGFR (Cockcroft-Gault or MDRD equation)\n  * PT within institutional normal range (unless on anticoagulation expected to affect PT, in which case PT cut off does not apply)\n  * PTT within institutional normal range (unless on anticoagulation expected to affect PTT, in which case PTT cut off does not apply)\n* Participants with known history or current symptoms of cardiac disease should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.\n* Ability to remain within 60 minutes of the administration site for 24 hours following cycle 1 day 15 dose of study drug.\n* The effects of epcoritamab on the developing human fetus are unknown. Women of child-bearing potential must agree to use adequate contraception starting with the first dose of study drug, for the duration of study participation, and for at least 4 months after the last dose of study intervention. Women must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Adequate contraception methods (see Appendix B for further guidance):\n\n  1. Male Partner Sterilization: When the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate.\n  2. Use of a combination of any two of the following (one from \"a\" and one from \"b\"):\n\n     1. Placement of an intrauterine device (IUD) or intrauterine system or established use of oral, injected, or implanted hormonal methods of contraception\n     2. Barrier methods of contraception: Male Condom or Occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fvaginal suppository.\n  3. True abstinence, defined as refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject.\n\nNonchildbearing potential is defined as follows:\n\n* ≥45 years of age and has not had menses for at least 12 consecutive months.\n* Subjects who have been amenorrhoeic for \\\u003C1 year must have, on at least two occasions prior to first dose of study drug, a follicle stimulating hormone value greater than 40 IU\u002FL; historical follicle stimulating hormone values are eligible\n* Post-bilateral oophorectomy (with or without hysterectomy) or post-tubal ligation at least six weeks prior to first dose of study drug. Documented oophorectomy can be confirmed with medical records of the actual procedure or confirmed by imaging (ultrasound or CT). Tubal ligation must be confirmed with medical records of the actual procedure. In the case of oophorectomy alone, reproductive status must be confirmed by follicle stimulating hormone level assessment as above.\n\n  * Women of childbearing potential (WOCBP) must have a negative highly sensitive serum pregnancy test at screening.\n  * Fertile men, defined as all males physiologically capable of conceiving offspring who are sexually active with a female partner of childbearing potential, must agree to use adequate contraception starting with the first dose of study drug, for the duration of study participation, and 4 months after completion of administration. Men must also agree not to donate sperm during this period. Men may agree to remain abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term or persistent basis) OR agree to use a male condom, and their female partner must use an additional highly effective contraceptive method with a failure rate of \\\u003C1% per year when having sexual intercourse if they are a WOCBP (including pregnant females). Please see Appendix B for contraception guidance.\n  * Ability to understand and the willingness to sign a written informed consent document by the participant or a legally authorized representative.\n\nExclusion Criteria:\n\n* Participant must not have used an investigational drug or approved systemic lymphoma therapy within 28 days preceding the first dose of study drug. Steroids for lymphoma disease control are permitted but must be stopped at least 7 days prior to the first dose of study drug.\n* Participants must not have received prior CD20\u002FCD3 bispecific antibody.\n* Participants must not have received prior autologous or allogeneic stem cell transplant.\n* Participants must not have received prior anti-CD19 CAR T-cell therapy.\n* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia. At the discretion of the overall PI, participants with residual toxicities \\> Grade 1 may be considered eligible if in the opinion of the overall PI the residual toxicity is not likely to interfere with the safety or efficacy assessment of the investigational regimen. For residual hematologic toxicities greater than Grade 1, see 3.1.7.\n* Participants must not have known central nervous system involvement by lymphoma.\n* Participants must not have a current life-threatening illness, medical condition, or organ system dysfunction (other than the disease under study) which, in the Investigator's opinion, could compromise the subject's safety or put the study at risk. Patients that have mild cognitive impairment or dementia are eligible per investigators' opinion.\n* Participants must not have an uncontrolled active infection. Localized fungal infection of skin or nails are permitted.\n* Participants must not have active uncontrolled autoimmune disease. Autoimmune disease under control with chronic systemic corticosteroids at a dose of 10 mg\u002Fday of prednisone or less, or equivalent corticosteroid, are eligible.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to epcoritamab. A history of an infusion reaction to CD20-directed therapy is not considered an allergic reaction.\n* Women who are pregnant are excluded from this study because it is unknown if epcoritamab can cause embryo-fetal harm when administered to a pregnant woman. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with epcoritamab, breastfeeding should be discontinued if the mother is treated with epcoritamab on study.\n* Participant must not have active uncontrolled HIV infection. Participants with HIV are eligible if disease is adequately controlled on an antiretroviral regimen that is in accordance with the current international AIDS Society guidelines, with adequate control defined by presence of both an undetectable viral load, a CD4 count \\>350, no evidence of AIDS-defining illness (with the exception of a lymphoma diagnosis), and no active opportunistic infections (infections controlled on appropriate anti-infective therapy are permitted).\n* Participant must not have active hepatitis B infection. Participants with positive HBV core antibody or HBV surface antigen at screening are eligible if HBV viral load is negative by PCR and they are on appropriate antiviral therapy.\n* Participant must not have active hepatitis C infection. Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained.\n\nNote: Participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing.\n\n-Subject has no known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. If a subject has signs\u002Fsymptoms suggestive of SARS-CoV-2 infection or has had recent known exposure to someone with SARS-CoV-2 infection, the subject must have a negative molecular (e.g., PCR) test, or 2 negative antigen test results at least 24 hours apart, to rule out SARS-CoV-2 infection.\n\nNote: SARS-CoV-2 diagnostic tests should be applied following local requirements\u002Frecommendations. Subjects who do not meet SARS-CoV-2 infection eligibility criteria must be screen failed and may only rescreen after they meet the following SARS-CoV-2 infection viral clearance criteria: No signs\u002Fsymptoms suggestive of active SARS-CoV-2 infection AND negative testing (molecular (e.g., PCR) result or 2 negative antigen test results at least 24 hours).\n\n* Participants must not have received a live virus vaccine within 28 days of first dose of study drug.\n* Participants must not have any known past or current malignancy other than inclusion diagnosis, except for:\n\n  1. Cervical carcinoma of Stage 1B or less.\n  2. Non-invasive basal cell or squamous cell skin carcinoma.\n  3. Non-invasive, superficial bladder cancer.\n  4. Prostate cancer with a current PSA level \\\u003C0.1 ng\u002FmL.\n  5. Any curable cancer with a complete response (CR) of \\>2 years duration\n* Uncontrolled seizure disorder\n* History of Progressive Multifocal Leukoencephalopathy (PML)",{"count":56,"type":23},[169],"The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed\u002Frefractory large B-cell lymphoma.",[369,370],"Relapsed Large B-cell Lymphoma","Refractory Large B-cell Lymphoma",[372,373,374,375,376,377],"Non-Transplant Eligible","Second Line Therapy","DLBCL","HGBCL","Naïve large B-cell lymphoma","First Line Therapy",{"date":379,"type":37},"2026-08-13",{"date":381,"type":37},"2025-06-05",{"date":383,"type":23},"2028-10-01",{"name":43,"class":44},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":24,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":45},"100492195","molar-mapping-oral-health-and-local-area-resources-100492195","NCT05688982","MOLAR: Mapping Oral Health and Local Area Resources","Inclusion Criteria:\n\n* To be eligible to participate in this study, an individual must meet all of the following criteria:\n\n  * No evidence of lack of capacity to provide verbal informed consent (as documented in the chart).\n  * Willing to comply with all study procedures and be available by phone for the duration of the study (as reported by the patient)\n  * Unmet oral health needs as ascertained by the Hope Home (adult) or Gazzaz (pediatric) questions\n  * Adult (age ≥18 years old) ED patient or pediatric ED patient (\\>1 year of age) presenting with parent or legal guardian. Parent will be the primary study participant but if age \\> 7 years, the child will provide assent for medical record review.\n  * Ability to communicate in English or Spanish (as reported by the patient)\n  * Emergency severity index (ESI) 2-5 (as documented in the electronic medical record)\n  * Residence within catchment area of 3-hospital region (defined by MGB home hospital catchment area) at initial enrollment (as reported by the patient)\n  * Working phone number\n\nExclusion Criteria:\n\n* Patients on involuntary holds (per electronic medical record review)\n* Presenting from carceral facilities (per electronic medical record review)\n* Presenting for acute mental health care under evaluation for Section 12 (per electronic medical record review)\n* Patients presenting for assistance with intimate partner violence (IPV) or care following sexual assault",{"count":392,"type":23},2927,[86],"The goal of this clinical trial is to test the impact of a screening and linkage intervention for adverse social determinants of health (aSDoH) on oral health linkage to care for emergency department patients. Researchers will compare three groups: Patients in Arm A will receive paper handouts with general oral health and aSDoH resources. Patients in Arm B will receive paper handouts with geographically-proximate oral health and aSDoH resources. Patients in Arm C will receive geographically-proximate oral health and aSDoH resources plus active navigational assistance.",[396],"Dental Diseases",{"date":379,"type":37},{"date":399,"type":37},"2023-08-25",{"date":401,"type":23},"2028-02-22",{"name":43,"class":44},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":409,"enrollmentInfo":410,"targetDuration":411,"studyType":57,"phases":4,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":45},"100448817","biomarker-profiling-in-individuals-at-risk-for-prion-disease-100448817","NCT05124392","OBSERVE: Biomarkers in Individuals at Risk for Prion Disease","Inclusion Criteria:\n\n1. Aged 18 - 85,\n2. One of the following:\n\n   * a. Known carrier of pathogenic PRNP mutation\n   * b. History of probable or definite prion disease in biological parent and other family members\n   * c. Non-carrier family members and\u002For unrelated previously enrolled negative control volunteers\n3. Medically safe to undergo blood draw, lumbar puncture and cognitive testing,\n4. Adequate visual and auditory acuity to complete cognitive testing,\n5. Fluent in English,\n6. At least 5 years of education,\n7. Capable of providing informed consent and following study procedures,\n\nExclusion Criteria:\n\n1. Any CNS disease other than asymptomatic or early prion disease, such as clinical stroke, brain tumor, multiple sclerosis, significant head trauma with persistent neurological or neurocognitive deficits, Alzheimer's disease, Parkinson's disease, frontotemporal lobar degeneration or other known neurodegenerative disease,\n2. History of alcohol or other substance abuse or dependence within the past two years,\n3. Any significant systemic illness or unstable medical condition or pregnancy that could represent safety risk or affect participation in the study,\n4. Coagulopathy or anti-coagulant therapy (such as Coumadin) increasing the risk for phlebotomy or lumbar puncture resulting in PT\u002FPTT and INR within 1.5 standard deviation over the upper normal limit.","85 Years",{"count":217,"type":23},"8 Years","We are doing this research to identify biomarkers in individuals who are at-risk for familial prion disease. We hope to use these biomarkers to predict timing of disease onset in pre-symptomatic individuals and to guide the direction of future clinical trials.",[414,415,416,417,418],"CJD (Creutzfeldt Jakob Disease)","Prion Diseases","GSS","FFI","Familial Fatal Insomnia",{"date":379,"type":37},{"date":421,"type":37},"2017-12-01",{"date":423,"type":23},"2027-06-01",{"name":43,"class":44},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":24,"phases":434,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":294,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":45},"100651818","phase-2-vilastobartretifanlimab-in-brca-or-palb2-deficient-pc-100651818","NCT07765836","Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC","A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)","EKLAVYA-HRD","Inclusion Criteria:\n\n* Participant must have histologically proven metastatic pancreatic cancer. Histologies including acinar cell carcinoma, carcinoma, ductal carcinoma, ductal adenocarcinoma, poorly differentiated or adenosquamous carcinoma are allowed.\n* Participant must have a germline or somatic pathogenic alteration in BRCA1, BRCA2, or PALB2 on tumor next generation sequencing (NGS) performed using a CLIA certified assay. Somatic pathogenic alterations detected on circulating tumor DNA need confirmation on tumor tissue NGS. Germline pathogenic alterations in BRCA1, BRCA2 or PALB2 do not require further confirmation on tumor NGS. All genomic reports be verified in writing (via email) by site and\u002For overall PI.\n* Participants must have measurable disease per RECIST version 1.1.\n* Participant must have at least one disease site which is amenable to safe biopsy and must agree to pre- and on-treatment biopsies (core, incisional, or excisional biopsy) of tumor site. In select cases biopsies can be waived after discussion with the Sponsor Investigator.\n* Participant must have had at least one but not more than two lines of cytotoxic chemotherapy for metastatic disease. Receipt of neoadjuvant or adjuvant therapy within the last 12 months may count as one line of therapy in metastatic setting for patients with recurrent disease who are being considered for the study. Receipt of targeted therapy such as KRAS inhibitor, or PARP inhibitor is not counted line of therapy. Recycling of the same agents from prior lines of cytotoxic chemotherapy after disease progression does not count as a new line of therapy.\n* Participant must have had prior platinum containing chemotherapy with at least a best response of stable disease. Participants with primary disease progression on platinum chemotherapy are ineligible.\n* Age ≥18 years\n* ECOG performance status of 0-2.\n* Participants must meet the following organ and marrow function as defined below:\n\n  * absolute neutrophil count ≥1,000\u002FmcL\n  * platelets ≥75,000\u002FmcL\n  * total bilirubin ≤ 1.5x institutional upper limit of normal (ULN). For patients with liver metastases or confirmed\u002Fsuspected Gilbert syndrome, total bilirubin ≤ 3 × ULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 2.5 × institutional ULN. For patients with liver metastases, AST and ALT ≤ 5 × ULN\n  * glomerular filtration rate (GFR) ≥30 mL\u002Fmin\u002F1.73 m\\^2\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* It is not known what effects study treatment has on human pregnancy or development of the embryo or fetus. Therefore, female patients participating in this study should avoid becoming pregnant, and male patients should avoid impregnating a female partner. Non-sterilized female patients of reproductive age group and male patients should use effective methods of contraception through defined periods during and after study treatment as specified below:\n\nFemale patients must meet 1 of the following:\n\n* Postmenopausal for at least 1 year before the screening visit, or\n* Surgically sterile, or\n* Women of childbearing potential must:\n\n  * agree to practice 1 effective method of contraception from the time of signing of the informed consent form through 5 months after the last dose of study drug.\n  * Agree not to breastfeed from the time of signing of the informed consent form through 5 months after the last dose of study drug\n  * Have a serum or urine pregnancy test to rule out pregnancy within 2 weeks prior to registration.\n* Male patients must agree to practice 1 effective method of contraception from the time of signing of the informed consent form through 7 months after the last dose of study drug.\n\nHighly effective methods of contraception include:\n\n* Sexual abstinence (no sexual intercourse)\n* Hormonal birth control\n* Intrauterine device (IUD) or intrauterine system (IUS)\n* Bilateral tubal ligation (both tubes tied)\n* Vasectomy - Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants with neuroendocrine tumors of the pancreas are excluded.\n* Prior anticancer therapy:\n\n  * Received prior treatment with anti-CTLA-4 therapy\n  * Received prior immune-checkpoint anti-PD-1\u002FPD-L1 therapy\n  * Received prior approved systemic anticancer therapy within 2 weeks or within its 5 half-lives prior to study treatment, whichever is shorter. Note: Long-standing hormonal therapy for prostate, breast, uterine, and adrenal cancer may be permitted to continue if it is deemed to be in the best interest of the patient, after discussion with the Sponsor Investigator.\n  * Received prior radiotherapy within 2 weeks prior to study treatment. Note: Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease\n* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia or stable, Grade ≤ 2 non-autoimmune chemotherapy-induced peripheral neuropathy.\n* Participants with uncontrolled intercurrent illness that would interfere with ability to participate in the opinion of the treating investigator.\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Has an active infection requiring systemic intravenous or oral therapy within 7 days of cycle 1 day 1.\n* Has received a live or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine. COVID-19 vaccination should not be given within 7 days of trial drug initiation.\n* Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (\\> 10 mg\u002Fday of prednisone or equivalent).\n\n  * Physiologic corticosteroid replacement therapy at doses ≤ 10 mg\u002Fday of prednisone or equivalent for adrenal or pituitary insufficiency and in the absence of active autoimmune disease is permitted.\n  * Participants with asthma that requires intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections may participate.\n  * Participants using topical, ocular, intra-articular, or intranasal corticosteroids (with minimal systemic absorption) may participate.\n  * Brief courses of corticosteroids for prophylaxis (eg, contrast dye allergy) or study treatment-related standard premedications are permitted.\n  * Replacement therapy (e.g. thyroxine, insulin) is not considered a form of systemic therapy and is allowed.\n* Has a history of immune-related (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease regardless of etiology.\n* Subjects with any condition requiring systemic treatment with either corticosteroids (\\>10mg\u002Fday of prednisone or equivalent) or other immunosuppressive medications within 14 days of treatment. Premedication for hypersensitivity reactions (e.g. to contrast for CT or gadolinium for MRI) or for prophylaxis of infusion related reactions is allowed.\n\nExceptions: use of inhaled, intranasal, intraocular, topical, and intraarticular joint injections are allowed\n\n* Participants with a known history of Human Immunodeficiency Virus (HIV) infection are excluded unless they meet all of the following criteria:\n\n  * Stable antiretroviral therapy (ART) for at least 12 weeks prior to enrollment\n  * No history of AIDS-defining conditions.\n  * CD4+ T-cell count ≥ 350 cells\u002Fmm\\^3 at screening\n  * HIV viral load ≤ 50 copies\u002FmL at screening.\n  * No significant comorbidities associated with HIV infection that could interfere with the safety or efficacy of the investigational treatment.\n  * No concurrent use of prohibited medications that may interfere with the study drug or cancer therapy\n* Has a history of severe hypersensitivity reaction (≥ Grade 3) to any study intervention and\u002For any of its excipients (refer to the IBs and\u002For approved product label for a list of excipients)\n* Participants with brain metastases (active brain metastases) or leptomeningeal disease are not eligible. Patients with treated brain metastases who are off systemic steroids \\> 2 weeks and have documented radiographic stability over 4 weeks since initial brain metastasis diagnosis may be considered in discussion with the Sponsor Investigator.\n* Has a history of allogeneic bone marrow\u002Fstem, cell or solid organ transplantation.\n* Unstable angina, myocardial infarction, congestive heart failure (New York Heart Association \\[NYHA\\] classification ≥ grade 2) or unstable vascular disease (eg, aortic aneurysm at risk of rupture, Moyamoya disease) that required hospitalization within 6 months prior to randomization, or other cardiac impairment that may affect the safety evaluation of the study drug (eg, poorly controlled arrhythmias, myocardial ischemia).",{"count":56,"type":23},[169],"This is a single arm, open-label, non-randomized multi-institution phase II trial of a Fc enhanced CTLA4 antibody, vilastobart, in combination with PD-1 antibody, retifanlimab, in patients with BRCA1, BRCA2 or PALB2 deficient pancreatic cancer (PC).",[437],"Pancreatic Cancer Metastatic",[439,440],"BRCA1, BRCA2, or PALB2 mutation","metastatic pancreatic cancer","2026-08-10",{"date":223,"type":37},{"date":444,"type":23},"2027-01",{"date":446,"type":23},"2030-12-31",{"name":43,"class":44},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":454,"minAge":82,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":24,"phases":457,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":294,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":467,"leadSponsor":469,"locationsCount":4},"100628317","routine-vs-early-postpartum-depression-screening-a-pragmatic-clinical-trial-100628317","NCT07460063","Routine vs. Early Postpartum Depression Screening: A Pragmatic Clinical Trial","Inclusion Criteria:\n\n1. Live birth, term (≥37 weeks) delivery at Massachusetts General Hospital\n2. Access to Patient Gateway, as to receive the electronic EPDS scale\n3. Primary obstetric provider at MGH or its affiliated clinics\n4. No recent history of depressive disorder as determined through diagnoses or medication use\\*\n5. Age ≥18 years old\n\nExclusion Criteria:\n\n1. A diagnosis code in the EHR for major depressive disorder, bipolar disorder, or psychotic disorder within the year prior to delivery\n2. Antidepressant, antipsychotic, or bipolar medication use within the year prior to delivery\n3. Age \\\u003C18 years old","FEMALE",{"count":456,"type":23},428,[86],"After having a baby, some women develop a condition called postpartum depression, or PPD, which can cause sadness, anxiety, and difficulty bonding with their newborn. Right now, most women aren't screened for PPD until about 6 to 8 weeks after giving birth, but this study wants to find out if checking earlier could help identify signs sooner. To test this, researchers will work with 428 women who deliver at an MGH hospital clinic and have no history of depression. Each woman will be randomly placed into one of two groups: one group will fill out a short depression questionnaire online at 2 to 3 weeks after delivery, while the other group will follow the usual process and complete the same questionnaire at their regular 6-week visit. The results will go to each woman's doctor, who will decide if any follow-up care is needed, just like they normally would. The study will follow each participant for 6 months after delivery to see whether earlier screening makes a difference.",[460],"Postpartum Depression (PPD)",[462,463,464],"postpartum","depression","depression screening",{"date":295,"type":37},{"date":124,"type":23},{"date":468,"type":23},"2028-01",{"name":43,"class":44},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":24,"phases":478,"briefSummary":479,"conditions":480,"keywords":482,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":45},"100594042","increasing-resiliency-among-early-post-treatment-lymphoma-survivors-100594042","NCT07014293","Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors","Inclusion Criteria:\n\n* English speaking adult (18 years or older at enrollment)\n* At least 6-months post-lymphoma diagnosis and within 2 years of completing active, curative treatment for lymphoma (includes surgery, chemotherapy\u002Fimmunotherapy\u002Fradiation therapy, or other)\n\nExclusion Criteria:\n\n* Active Psychiatric or cognitive comorbidity as determined by site PI or treating clinician\n* Unwilling or unable to participate using telehealth platform",{"count":477,"type":23},254,[86],"The goal of this clinical trial is to learn if a mind body resilience group program can help increase lymphoma survivors' ability to cope with and manage the challenges that come with the transition into early post treatment survivorship.",[481],"Lymphoma",[483,484,485,486],"coping","psychosocial intervention","survivorship","resilience","2026-08-08",{"date":351,"type":37},{"date":490,"type":23},"2026-08-31",{"date":492,"type":23},"2030-07-01",{"name":43,"class":44},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":24,"phases":502,"briefSummary":503,"conditions":504,"keywords":505,"overallStatus":294,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":511,"leadSponsor":513,"locationsCount":45},"100593976","a-resilience-based-approach-to-improve-long-term-quality-of-life-in-post-treatment-lymphoma-survivorship-100593976","NCT07013435","A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship","Thriving Beyond Treatment: A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship.","Inclusion Criteria:\n\n* English or Spanish speaking adults (18+ at time of enrollment)\n* Within 2 years of completing active, curative treatment for lymphoma (includes surgery, chemotherapy, immunotherapy, radiation therapy, or other)\n\nExclusion Criteria:\n\n* Active psychiatric or cognitive comorbidity as determined by the site PI or treating clinician",{"count":477,"type":23},[86],"The goal of this trial is to learn if a resilience intervention can lead to improvements in lymphoma survivors' quality of life.",[481],[506,484,507,508,486],"quality of life","supportive care","cancer survivorship",{"date":351,"type":37},{"date":490,"type":23},{"date":512,"type":23},"2030-08",{"name":43,"class":44},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":24,"phases":523,"briefSummary":524,"conditions":525,"keywords":528,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":128},"100581392","phase-2-zanubrutinib-obinutuzumab-sonrotoclax-boson-or-bgb-16673-obinutuzumab-sonrotoclax-doson-in-tn-cllsll-100581392","NCT06849713","Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL\u002FSLL","A Multicenter Phase 2 Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax (BOSon) or Tacabrutideg (BGB-16673), Obinutuzumab, and Sonrotoclax (DOSon) in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Inclusion Criteria:\n\n* Participant must have CLL or SLL (WHO criteria).\n* Participant must require treatment according to iwCLL guidelines.\n* Participants must have no prior systemic therapy for CLL or SLL, except:\n\n  * Prior local radiation for symptomatic disease is permitted.\n  * Short course systemic corticosteroids is permissible for disease control, improvement of performance status, or non-cancer indication. However, duration of steroid course must be ≤14 days with maximum daily dose of ≤100 mg prednisone, ≤20 mg dexamethasone, or equivalent, and must be discontinued prior to study treatment (last dose may be administered up until the morning of \u002F prior to study treatment). Inhaled steroids, topical steroids, and replacement \u002F stress corticosteroids are permitted independent of above rules. In cases of autoimmune complications of CLL (e.g., ITP or AIHA), steroid usage is permitted.\n* Age ≥18 years.\n* ECOG performance status of 0, 1 or 2.\n* Participants must meet the following organ and marrow function as defined below:\n\n  * absolute neutrophil count ≥1,000\u002FµL without growth factor support (filgrastim within 5 days or PEGfilgrastim within 10 days of test), unless clearly due to disease under study (per investigator)\n  * platelets ≥75,000\u002FµL, or ≥20,000\u002FµL if clearly due to disease under study (per investigator)\n  * total bilirubin ≤2 x institutional upper limit of normal (ULN), or ≤3 x institutional ULN if due to Gilbert's syndrome, or with PI approval if clearly due to disease under study\n  * AST(SGOT)\u002FALT(SGPT) ≤2.5 x × institutional ULN\n  * CrCl or GFR ≥30 mL\u002Fmin as estimated by the Cockcroft-Gault equation, the CKD-EPI equation, or as measured by 24-hour urine collection\n* For females of childbearing potential, a serum pregnancy test must be negative within screening period.\n* For female patients of childbearing potential: agreement to use highly effective form(s) of contraception (i.e., one that results in a low failure rate \\[\\\u003C1% per year\\] when used consistently and correctly) or remain abstinent (refrain from heterosexual intercourse) during the treatment period and to continue its use for ≥ 30 days after the last dose of zanubrutinib or BGB-16673 or ≥ 7 days after the last dose of sonrotoclax, and for ≥18 months fter the last dose of obinutuzumab (whicher is later).\n\n  * A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (\\>12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and\u002For uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations.\n  * Examples of contraceptive methods with a failure rate of \\\u003C 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Hormonal contraceptive methods must be supplemented by a barrier method.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n* For men with a female partner of childbearing potential or a pregnant female partner: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom in addition to 1 of the highly effective methods of contraception listed below, from the time of taking the first dose of study drug , during the treatment period and to continue its use for ≥ 30 days after the last dose of zanubrutinib or BGB-16673 or ≥ 7 days after the last dose of sonrotoclax, and for ≥18 months fter the last dose of obinutuzumab (whicher is later).\n\n  --The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n* Willingness to not donate or bank sperm or oocytes during the entire study treatment period and after treatment discontinuation for for ≥ 30 days after the last dose of zanubrutinib or BGB-16673 or ≥ 7 days after the last dose of sonrotoclax, and for ≥18 months fter the last dose of obinutuzumab (whicher is later).\n* Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged)\n\nExclusion Criteria:\n\n* Known histologic transformation from CLL or SLL to an aggressive lymphoma (i.e., Richter's transformation).\n* Known central nervous system involvement with CLL or SLL.\n* Other diagnosis of active malignancy or systemic therapy within 2 years of study treatment. Note: An active malignancy or systemic therapy within 2 years for another malignancy, whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Also, local\u002Fregional therapy with curative intent such as surgical resection or localized radiation at any timepoint is permitted.\n* Any uncontrolled illness that in the opinion of the investigator would preclude administration of study therapy (e.g., significant active infections, hypertension, angina, arrhythmias, pulmonary disease, or autoimmune dysfunction).\n* Congestive heart failure, New York Heart Association III\u002FIV. Unstable angina within 3 months before screening, myocardial infarction within 6 months before screening. History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes). Heart rate-corrected QT interval \\> 480 milliseconds based on Fridericia's formula corrected for bundle branch block as appropriate. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place.\n* Receipt of a live-virus vaccine within 28 days prior to initiation of study treatment or need for live-virus vaccine at any time during study treatment.\n* Active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds).\n* Known bleeding diathesis. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.\n* Prior major surgical procedure within 4 weeks of study, or anticipation of need for a major surgical procedure during the course of the study.\n* Known CNS hemorrhage or stroke within 6 months of the study.\n* History of progressive multifocal leukoencephalopathy.\n* History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C infection.\n\n  * Patients with a history of HIV infection that is well controlled on antiretroviral therapy are eligible if all of the following criteria are met: (1) undetectable HIV viral load by standard clinical assay AND (2) CD4+ T cell count of \\>\u002F=200 cells\u002Fmicroliter). NOTE: Many HIV regimens are excluded based on drug interactions, and concomitant antiretroviral therapy must be acceptable per protocol.\n  * Participants with occult or prior HBV infection (defined as positive total hepatitis B core antibody \\[HBcAb\\] and negative HBsAg) may be included if HBV DNA is undetectable, and if the participant is willing to take appropriate anti-viral prophylaxis as indicated and HBV DNA monitoring on study.\n  * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n\nKnown condition or other clinical situation resulting in inability to swallow oral medications, or that would impair absorption of oral medications.\n\n* Participant in a separate investigational therapeutic trial unless authorized by the PI.\n* Concurrent therapy with, or administration within 5 half-lives 14 days prior to the first dose of study drug (whichever is shorter), with moderate or strong inhibitors or inducers of CYP3A.\n* Concomitant use of warfarin or warfarin derivatives.\n* Concomitant use of dual antiplatelet therapy.\n* Prior systemic therapy for CLL or SLL, except for localized radiation or corticosteroids as per 3.1.3.\n* Prior anti-CD20 monoclonal antibody therapy for any indication (malignant or non-malignant).\n* Participants with a contraindication to obinutuzumab based on known hypersensitivity (IgE-mediated) reaction to obinutuzumab or to any of its excipients. Hypersensitivity to zanubrutinib or sonrotoclax.\n* Consumption of one or more of the following within 3 days prior to the first dose of study drug: grapefruit or grapefruit products, Seville oranges including marmalade containing Seville oranges, or Star fruit (carambola).\n* Known psychiatric illness or social situation that would interfere with study adherence.\n* Pregnant women are excluded from this study given potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued prior to the first dose of study drug if the mother is treated.\n* Uncontrolled autoimmune anemia and\u002For autoimmune thrombocytopenia (eg, idiopathic thrombocytopenia purpura), e.g., with need for ongoing corticosteroid treatment (see 3.2.24).\n* Requires ongoing need for corticosteroid treatment. NOTE: Systemic corticosteroids must be fully tapered off\u002Fstopped before first study drug.\n* Uncontrolled hypertension at Screening, defined as systolic blood pressure \\> 170 mmHg and diastolic blood pressure \\> 105 mmHg by ≥ 2 consecutive measurements. In patients NOT meeting these parameters for uncontrolled hypertension, repeat blood pressure measurement is NOT required for eligibility.\n* Prior invasive fungal infections, except if patient agrees to receive secondary antifungal prophylaxis during the entire treatment period (Cohort 2 Only).\n* Patients with known contraindication to azole antifungal agents, including hypersensitivity reactions (Cohort 2 Only).",{"count":522,"type":23},80,[169],"The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",[526,527],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma (SLL)",[529,530,531],"CLL","SLL","untreated",{"date":351,"type":37},{"date":534,"type":37},"2025-05-16",{"date":536,"type":23},"2030-03-01",{"name":43,"class":44},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":454,"minAge":20,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":548,"briefSummary":549,"conditions":550,"keywords":552,"overallStatus":294,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":128},"100651372","telehealth-intervention-for-symptom-management-and-adherence-to-adjuvant-endocrine-therapy-100651372","NCT07759947","Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy","STRIDE: Evidence-Based Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy","STRIDE","Inclusion Criteria:\n\n* Female ≥ 21 years old\n* Diagnosis of early-stage (0-IIIb), hormone receptor positive (ER+\u002FPR+) breast cancer\n* Completed primary treatment (surgery, chemotherapy, and\u002For radiation)\n* Within 3 to 12 months of starting oral adjuvant endocrine therapy (AET)\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Ability to read and respond in English or Spanish\n* Distress about AET ≥ 4 on a 0-10 scale\n\nExclusion Criteria:\n\n* Cognitive impairment, uncontrolled psychosis, or serious mental illness prohibiting participation in the study as per the judgment of the treating oncologist\n* Enrolled in a clinical trial for AET",{"count":547,"type":23},400,[86],"The goal of this study is to demonstrate the efficacy of an evidence-based, small-group, telehealth intervention ('STRIDE') for improving patients' ability to cope with side effects from adjuvant endocrine therapy (AET) and adhere to AET medication regimens for patients with hormone-sensitive breast cancer.",[551],"Hormone Receptor Positive Breast Cancer",[551,553,554,555,556],"Adjuvant Endocrine Therapy Adherence","Coping","Supportive Care","Behavioral Intervention","2026-08-07",{"date":295,"type":37},{"date":560,"type":23},"2027-02-01",{"date":562,"type":23},"2031-06-01",{"name":43,"class":44},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":24,"phases":573,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":294,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":584,"leadSponsor":586,"locationsCount":128},"100651188","randomized-evaluation-of-operating-room-extubation-after-cardiac-surgery-100651188","NCT07757880","Randomized Evaluation of Operating Room Extubation After Cardiac Surgery","Randomized Evaluation of Operating Room Extubation Versus Intensive Care Unit Extubation After Cardiac Surgery","Inclusion Criteria:\n\n* Adults (age 18+) scheduled for elective cardiac surgery requiring cardiopulmonary bypass\n* Low perioperative risk defined as STS Predicted Risk of Mortality (PROM) ≤ 3% based on the latest STS Adult Cardiac Surgery Database (ACSD) Risk Calculator\n* Deemed appropriate for OR extubation preoperatively by the attending cardiac surgeon\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Underlying pulmonary disease requiring use of home supplemental oxygen\n* Pre-capillary pulmonary hypertension (mPAP ≥ 25 mmHg or PVR \\> 2 Wood units) on most recent right heart catheterization for any patient for which there is suspicion for pulmonary hypertension at the time of preoperative evaluation\n* Preoperative right ventricular dysfunction greater than mild on most recent echocardiogram\n* Obstructive sleep apnea with home CPAP or biPAP use or recommended use\n* Neuromuscular disease associated with respiratory muscle weakness including myasthenia gravis, Lambert-Eaton myasthenic syndrome, or muscular dystrophy\n* Airway abnormalities including tracheostomy, history of difficult mask ventilation, history of difficult intubation requiring fiberoptic rescue or multiple (\\>2) attempts, known anatomic abnormalities including limited mouth opening (\\\u003C 3cm), severe micrognathia, tracheal stenosis, or tracheal compression due to mass or goiter\n\nWe will also exclude patients undergoing the following procedures:\n\n* Transplant surgery\n* Pulmonary thromboendarterectomy\n* Implantation of mechanical circulatory support including LVAD, Impella, intra-aortic balloon pump, RVAD, or ECMO",{"count":572,"type":23},120,[86],"We are studying whether waking patients up and removing the breathing tube (also known as \"extubation\") in the operating room after cardiac surgery improves postoperative recovery without causing harm.",[576],"Cardiac Surgery",[578,579,580],"Extubation","Cardiac surgery","Cardiac surgery recovery","2026-08-06",{"date":351,"type":37},{"date":71,"type":23},{"date":585,"type":23},"2027-03",{"name":43,"class":44},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":24,"phases":597,"briefSummary":598,"conditions":599,"keywords":603,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":607,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":45},"100640994","hips-feasibility-randomized-controlled-trial-100640994","NCT07586397","HIPS Feasibility Randomized Controlled Trial","HIPS Feasibility RCT Testing a Mind-Body Intervention to Improve Recovery for Individuals With Chronic Hip Pain","HIPS-RCT","Inclusion Criteria:\n\n1. Presenting with chronic (lasting ≥3 months) hip joint-related pain\n2. Fluent in English\n3. Age ≥18yr \\[If ≥45yr, the physician will confirm no osteoarthritis via X-ray (Kellgren Lawrence \\[KL\\] grade 0-1)\\]\n4. Score ≥3 for current hip pain on the Pain-VAS\n5. Psychological risk factor for the maintenance of pain by meeting ≥1 of the criteria listed below:\n\n   1. Score ≥ 20 on the PCS\n   2. Score ≤ 40 on the PSEQ\n   3. Score ≥ 17 on the TSK-11\n6. Exhibits sedentariness or dissatisfaction with physical activity by meeting ≥1 of the criteria listed below:\n\n   1. Physically active \\\u003C 150mins\u002Fweek according to the IPAQ-SF\n   2. Hip pain interferes with the ability to be physically active\n   3. Dissatisfaction with the current physical activity level\n\nExclusion Criteria:\n\n1. Previous surgery on the symptomatic (painful) hip\n2. Current pain referred from the lower back",{"count":596,"type":23},50,[86],"The goal of this clinical trial is to conduct a randomized controlled trial (RCT) to test the feasibility of two dose- and time-matched pain management programs, delivered via live video, for adults with chronic (lasting at least 3 months) and non-arthritic hip-related pain (HRP). Following pre-determined benchmarks, findings from this trial will be used to assess the feasibility, credibility, and acceptability of both programs (HIPS-1, HIPS-2). In preparation for a future clinical trial powered to test efficacy, we will optimize the protocol for patient recruitment, study protocol, and fidelity materials.",[600,601,602],"Hip Pain Chronic","Hip Pain","Physical Medicine and Rehabilitation",[604,605,606],"Intervention feasibility","Randomized controlled trial","Behavioral intervention development",{"date":441,"type":37},{"date":609,"type":37},"2026-07-20",{"date":611,"type":23},"2028-06-01",{"name":43,"class":44},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":136,"sex":18,"minAge":621,"maxAge":409,"enrollmentInfo":622,"targetDuration":4,"studyType":24,"phases":623,"briefSummary":624,"conditions":625,"keywords":628,"overallStatus":294,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":632,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":4},"100616779","creatine-and-perioperative-brain-health-100616779","NCT07310043","Creatine and Perioperative Brain Health","Creatine Intervention in Older Adults to Improve Perioperative Brain Health: a Randomized Controlled Trial (CREATE Trial)","CREATE","Inclusion Criteria:\n\n* Patients scheduled for elective surgery under general anesthesia\n\nExclusion Criteria:\n\n* History of creatine deficiency disorders\n* Renal or neurodegenerative disorders\n* History of stroke or significant head trauma, presence of intracranial mass lesions\n* Inability to give informed consent","60 Years",{"count":572,"type":23},[86],"The overall goal of this study is to evaluate the feasibility of perioperative oral creatine supplementation and to explore its effects on cognitive function and physiological responses to surgery in older adults. Creatine is commonly used to enhance athletic performance, but it can also have positive effects on the brain. Since surgery can alter thinking, memory, and attention patterns in some patients, we will assess whether creatine affects these changes in older adults undergoing surgery.",[626,627],"Neurocognitive Disorders","Postoperative Delirium",[629,630,631],"Perioperative Brain Health","Creatine","Perioperative Neurocognitive Disorders",{"date":441,"type":37},{"date":634,"type":23},"2026-09-01",{"date":636,"type":23},"2028-08-30",{"name":43,"class":44},""]